Agoracom Blog Home

Posts Tagged ‘smallcap stocks’

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 11:38 AM on Tuesday, December 15th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids. 

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
  • iAmHealth Distribution UG (Distribution – Germany)

Completed Trademark Registration in the EU, UK and Switzerland

  • Completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

Hub On AGORACOM / Corporate Profile

Innocan $INNO.ca Pharma to Participate in the Lytham Partners End of Year 1×1 Conference $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:08 PM on Thursday, December 3rd, 2020
Innocan-Blog
  • Announced that it was invited by one of the leading IR agencies in the U.S., Lytham Partners, to participate in its End of Year 1×1 Conference (the “Conference”) from December 7-11, 2020.
  • CEO Iris Bincovich will be participating on behalf of Innocan and will showcase the Company in one-on-one meetings at the Conference.

Herzliya, Israel and Calgary, Alberta–(December 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that it was invited by one of the leading IR agencies in the U.S., Lytham Partners, to participate in its End of Year 1×1 Conference (the “Conference”) from December 7-11, 2020. CEO Iris Bincovich will be participating on behalf of Innocan and will showcase the Company in one-on-one meetings at the Conference.

To arrange a one on one meeting, please contact Ben Shamsian of Lytham Partners at [email protected] or visit https://lythampartners.com/virtual/.

CEO Iris Bincovich states: “We are glad that Innocan was selected by Lytham Partners to participate in this important conference. This invitation outlines that we are on a promising path within our field of scientific work in combining CBD with liposomes and exosomes, to target serious diseases like Epilepsy, Alzheimer or Covid-19.”

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Innocan $INNO.ca Reports Q3 2020 Financial Results $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:30 AM on Wednesday, December 2nd, 2020
Innocan-Blog

The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:

  • Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
  • Current assets of C$3.6 million as compared to C$3.2 million;
  • Total assets of C$3.7 million as compared to C$3.3 million; and
  • Current liabilities of C$3.07 million as compared to C$1.4 million.

Herzliya, Israel and Calgary, Alberta–(December 2, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today its financial and business results for the three and nine months period ended September 30, 2020 (the “Financial Statements“) and provide highlights and comments on these results. This news release should be read in conjunction with the Financial Statements and corresponding Management’s Discussion and Analysis available on the Company’s profile at www.sedar.com. The Company’s Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS“).

“This has been a milestone quarter for Innocan. After successfully completing our $5.1M financing, we have laid the groundwork for full commercialization of our CBD based products. We are completing the manufacturing process in Europe and the USA and have received regulatory approvals for marketing in Europe and the USA” stated Iris Bincovich, Chief Executive Officer of Innocan.”

Business highlights for the three months period ended September 30, 2020

On June 5, 2020, the Company announced the commencement of commercial production of its Derma CBD line in Portugal. The first product currently being manufactured is the patent pending Relief & Go Pain Relief spray.

On June 26, 2020, the Company announced the results from the first dermal clinical study of the Relief & Go and SHIR product lines. The double-blind, randomized control study assessed the tolerance degree of the Company’s CBD topical products and demonstrated the products to be non-irritating to the skin.

On July 9, 2020, the Company announced its collaboration with Recipharm, Israel (“Recipharm“) to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites more than 30 facilities across 10 countries offering a range of services with a focus on two areas of operation: pharmaceutical development services and manufacturing services.

On July 13, 2020, the Company announced that it received notice from the U.S. Food and Drug Administration that Innocan’s over-the-counter Relief & Go Pain Relief spray received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD. The Relief & Go Pain Relief spray is designed to target and relieve pain related to muscles and joints. The unique formulation is administered with a simple dose by spray, roll-on or lotion.

On August 6, 2020, the Company announced that its SHIR CBD Derma Cosmetic product line successfully passed safety assessments in accordance with European Union (EU) cosmetic regulation No. 1223/2009 and received an EU Cosmetic Product Safety Report for marketing in the European Union.

On August 11, 2020, the Company announced it entered into a manufacturing and distribution agreement (the “ESI Agreement“) with Endless Sky Incorporated (“ESI“), a large-scale Canadian cannabis extractor based in Calgary, Alberta. Under the ESI Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief & Go Pain Relief spray and cream and the SHIR Eye Serum, Face Cream and Night Cream. The ESI Agreement is conditional upon ESI receiving Health Canada approval no later than December 31, 2020. According to the ESI agreement, ESI shall pay Innocan a cash license fee per product as well as royalties based on net sales of the products distributed by ESI. The ESI Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months, each based on ESI achieving minimum sales targets for the previous 12-month period.

On August 19, 2020, the Company entered into a manufacture and supply agreement with GNB Swiss Investments SA to manufacture and supply GNB Swiss Investments SA products based on Innocan’s formulas, which will be distributed by GNB Swiss Investments SA under its own brand.

On August 20, 2020, the Company announced that Innocan entered into a distribution agreement (the “Cloud 9 Agreement“) with Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland. Under the terms of the Cloud 9 Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Cloud 9 Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Cloud 9 Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.

On September 15, 2020, the Company announced it completed a cosmetic clinical study examining the impact of its SHIR Premium CBD Facial Serum, containing 300 mg of cannabidiol, on skin hydration.

Financial highlights for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:

The following are financial highlights of Innocan’s operating results for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:

Research and development expenses amounted to C$654,000 for the three months period ended September 30, 2020 compared to C$149,000 for the three months period ended September 30, 2019. The increase is primarily attributable to an increase in research expenses due to the new research agreements entered into during the nine months period ended September 30, 2020 with Yissum Research Development Company and Ramot at Tel Aviv University, along with an increase in patent application expenses.

Selling, general and administrative expenses amounted to C$902,000 for the three months period ended September 30, 2020 compared to C$1,858,000 for the three months period ended September 30, 2019. The decrease in selling, general and administrative expenses is primarily attributable to the reduction of issuance expenses.

The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:

  • Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
  • Current assets of C$3.6 million as compared to C$3.2 million;
  • Total assets of C$3.7 million as compared to C$3.3 million; and
  • Current liabilities of C$3.07 million as compared to C$1.4 million.

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled release liposome to be administrated by injection. Innocan plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research at the Hebrew University, to test the liposome platform on several potential indications. Innocan is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

AGORACOM Small Cap 60: Innocan $INNO.ca #CBD Products Ready For Launch With Positive Clinical Test Results $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 2:33 PM on Monday, November 30th, 2020
Innocan-Blog

Innocan (INNO:CSE) has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

Innocan $INNO.ca Enters Into Distribution Agreement to Sell its #CBD Derma Cosmetic Products in Germany $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:10 PM on Wednesday, November 11th, 2020
Innocan-Blog
  • Entered into a distribution agreement with iAmHealth Distribution UG, a CBD products provider in Germany to sell the Company’s SHIR Beauty and Relief & Go product lines in Germany.
  • iAmHealth will distribute Innocan’s unique cosmetic CBD products in Germany on a non-exclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties.
  • The parties intend to carry out the Agreement immediately following the completion of all registration and regulatory requirements in Germany.

Herzliya, Israel and Calgary, Alberta–(November 11, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel“) has entered into a distribution agreement dated 4, 2020 (the “Agreement“) with iAmHealth Distribution UG (“iAmHealth“), a CBD products provider in Germany to sell the Company’s SHIR Beauty and Relief & Go product lines in Germany.

Under the terms of the Agreement, iAmHealth will distribute Innocan’s unique cosmetic CBD products in Germany on a non-exclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Agreement immediately following the completion of all registration and regulatory requirements in Germany.

Nina Wlodarczyk, iAmHealth’s Managing Director commented: “Our iAmHealth team comes from the medical industry with research based on science. As cannabidiol (“CBD”) became more available and gained popularity in Germany, we wanted to make our contribution and create a place for all of our existing customers, as well as people who are looking for new products they can trust, and with a high level of efficacy. We believe Innocan, as a pharmaceutical oriented company, is the perfect fit to complement the range of our existing products that we offer to the German consumer.”

Iris Bincovich, Innocan’s Founder and CEO, commented: “We are excited to start our product distribution in Germany. This is one of several distribution agreements that we have signed in Europe. I believe iAmHealth will provide a premier distribution channel for our SHIR and Relief & Go product lines.”

iAmHealth GmbH

iAmHealth Distribution UG, a subsidiary of iAmHealth GmbH (www.iam.health), is a collaborative group of multidisciplinary professionals from various sectors focusing on therapeutic formulations, including clinical trials, product development and manufacturing. iAmHealth has built a network of trustworthy Medical, R&D, Financial and Legal partners to supply and provide valuable expertise and extensive knowledge. iAmHealth is dedicated to the online distribution of various cosmetics and lifestyle products, utilizing an advanced, Artificial Intelligence driven e-commerce platform, enabling complete efficacy and security to a wide range of end consumers. iAmHealth strives to offer the very best cosmetics, natural products and CBD, which are highly trustworthy and proven, at reasonable prices, which support and increase the well-being of its customers.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining CBD with other products. Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Could #Cannabis Eliminate The High-Cost And High-Stakes Of Current #Psoriasis Medicines? SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 6:04 PM on Thursday, October 29th, 2020

SPONSOR: Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. In addition, the company filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.

  • “The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027.
Innocan-Blog

Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?

  • Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol.
  • The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 
  • A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis.
  • Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

By: Kate-Madonna Hindes

The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well. 

Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore. 

A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.

Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.

Image Credit: Aleksandr_Kravtsov | Getty Images via The Fresh Toast

Can CBD alone help psoriasis? 

Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 

A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.

Source: https://www.greenentrepreneur.com/article/358275

Innocan Pharma’s $INNO.ca Relief & Go #CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 5:12 PM on Tuesday, October 27th, 2020
Innocan-Blog
  • R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union
  • “We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

Herzliya, Israel and Calgary, Alberta–(October 27, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union.



Relief & Go

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/6922/66954_657f8b1b940c6910_002full.jpg

Innocan Israel, a wholly owned subsidiary of the Company, with its patent-pending unique formulation “Relief & Go CBD Spray” combines the known benefits of active ingredients such as Menthol and Camphor with CBD and Magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals. 

Innocan Israel’s CTO, Mr. Nir Avram has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.

Nir is Vice President of Research & Development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.

“We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:35 AM on Friday, October 23rd, 2020
Innocan-Blog
  • Announced the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19
  • The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020
  • study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors
  • The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020
  • Demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

Herzliya, Israel and Calgary, Alberta–(October 23, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020 outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

Innocan Israel, a wholly owned subsidiary of the Company, together with Tel Aviv University Prof. Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus’s direct damage and its cytokine storm. This product is planned to act as a “guided missile” to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

Prof. Offen added: “The recent publications which support our unique approach is exciting. The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction. We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable